When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation
Journal of Market Access & Health Policy · 20.04.2026 · 14 (2) · 23
DOI: 10.3390/jmahp14020023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 20.04.2026. Verfasst von Walter Van Dyck und 5 weiteren Autor:innen. Beteiligte Einrichtung: Healthcare Management Centre, Vlerick Business School, 9000 Ghent, Belgium. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation Flanders (FWO).
Abstract (Originalsprache)
Spreading payments over time by means of annuities has been proposed as a means to address the affordability challenge of funding very expensive advanced therapies, especially within managed entry agreements. This study aims to examine when annuities (in contrast with a single upfront payment) offer a viable solution for both healthcare payers and manufacturers to fund one-time advanced therapies. We put forward four conditions under which annuity-based payments can be considered an acceptable payment strategy: (1) excessive budget impact, (2) cost equivalence with upfront payment, (3) compensation for financial risk and (4) a limited annuity period. We develop an exploratory model that simulates how the budget impact of annuity-based payments for advanced therapies meets these conditions across several economic and epidemiological scenarios. Given our model parameter values, results suggest that annuity-based payments are most suitable when the initial patient volume (prevalence) significantly exceeds annual new cases (incidence), and when the financial risk premium for the annuity-based payment scheme does not exceed the social discount rate. While further refinement of the model is needed, this study demonstrates that annuity-based payments can only help control the annual budget need when the focus is on a high-prevalence disease, and the therapy is financed through health impact bonds issued by a governmental payer. This arrangement ensures a low-risk premium, which is typically only available to public payers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Healthcare Management Centre, Vlerick Business School, 9000 Ghent, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
- Faculty of Economics and Business Administration, Ghent University, 9000 Ghent, Belgium.
- Leuven Institute for Healthcare Policy, KU Leuven, 3000 Leuven, Belgium.
ORCID-Profile: Walter Van Dyck, Jeroen Luyten, Steven Simoens
Förderung
- Research Foundation Flanders (FWO)
Zitieren
APA
Van Dyck, W., Michelsen, S., Veredas, D., Huys, I., Luyten, J., & Simoens, S. (2026). When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation. Journal of Market Access & Health Policy, 14(2), 23. https://doi.org/10.3390/jmahp14020023
Vancouver
Van Dyck W, Michelsen S, Veredas D, Huys I, Luyten J, Simoens S. When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation. Journal of Market Access & Health Policy. 2026;14(2):23. doi:10.3390/jmahp14020023
BibTeX
@article{VanDyck2026,
author = {Van Dyck, Walter and Michelsen, Sissel and Veredas, David and Huys, Isabelle and Luyten, Jeroen and Simoens, Steven},
title = {When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation},
journal = {Journal of Market Access & Health Policy},
year = {2026},
volume = {14},
number = {2},
pages = {23},
doi = {10.3390/jmahp14020023}
}
EUVIMED